Analysts Expect Biomerica, Inc. (BMRA) Will Post Quarterly Sales of $1.42 Million

Equities research analysts forecast that Biomerica, Inc. (NASDAQ:BMRA) will post $1.42 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Biomerica’s earnings. The lowest sales estimate is $1.32 million and the highest is $1.52 million. Biomerica reported sales of $1.13 million during the same quarter last year, which indicates a positive year over year growth rate of 25.7%. The business is expected to report its next earnings report on Thursday, August 29th.

According to Zacks, analysts expect that Biomerica will report full year sales of $5.78 million for the current financial year, with estimates ranging from $5.61 million to $5.95 million. For the next year, analysts anticipate that the firm will report sales of $6.08 million, with estimates ranging from $5.79 million to $6.37 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Biomerica.

Biomerica (NASDAQ:BMRA) last issued its quarterly earnings data on Monday, April 15th. The company reported ($0.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.02). The business had revenue of $1.26 million during the quarter, compared to the consensus estimate of $1.58 million. Biomerica had a negative return on equity of 45.72% and a negative net margin of 36.36%.

A hedge fund recently bought a new stake in Biomerica stock. Perritt Capital Management Inc. acquired a new stake in shares of Biomerica, Inc. (NASDAQ:BMRA) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 40,000 shares of the company’s stock, valued at approximately $68,000. Perritt Capital Management Inc. owned approximately 0.43% of Biomerica at the end of the most recent reporting period. 0.94% of the stock is owned by institutional investors.

Biomerica stock traded down $0.06 during midday trading on Wednesday, hitting $2.40. The stock had a trading volume of 15,100 shares, compared to its average volume of 24,528. The firm has a market capitalization of $23.92 million, a price-to-earnings ratio of -14.12 and a beta of 1.35. Biomerica has a 52-week low of $1.60 and a 52-week high of $4.33.

About Biomerica

Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.

Read More: Stock Symbols, CUSIP and Other Stock Identifiers

Get a free copy of the Zacks research report on Biomerica (BMRA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with's FREE daily email newsletter.